Download Files:

CD2665

$50$695

Products Details

Product Description

– CD2665 is an orally active and selective RAR-β,γ antagonist, with Kd values of 306 nM, 110 nM for RAR-β and RAR-γ, repectively[1][3].

Web ID

– HY-107437

Storage Temperature

– -20°C, 3 years (Powder)

Shipping

– Blue Ice

Applications

– Metabolism-sugar/lipid metabolism

Molecular Formula

– C31H34O5

References

– [1]Alfos S, Boucheron C, et al. A retinoic acid receptor antagonist suppresses brain retinoic acid receptor overexpression and reverses a working memory deficit induced by chronic ethanol consumption in mice. Alcohol Clin Exp Res. 2001 Oct;25(10):1506-14.|[2]Koyama E, et al.Premature Growth Plate Closure Caused by a Hedgehog Cancer Drug Is Preventable by Co-Administration of a Retinoid Antagonist in Mice. J Bone Miner Res. 2021 Jul;36(7):1387-1402.|[3]Kim MJ, et al. The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53.

CAS Number

– 170355-78-9

Molecular Weight

– 486.60

Compound Purity

– 99.91

SMILES

– COCCOCOC1=CC2=CC=C(C3=CC=C(C(O)=O)C=C3)C=C2C=C1C45C[C@H](C6)C[C@H](C[C@H]6C5)C4

Clinical Information

– No Development Reported

Research Area

– Metabolic Disease

Solubility

– DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– RAR/RXR

Pathway

– Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.